PCM
AXSM icon

Prelude Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Prelude Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,500
Closed -$699K – 1818
2021
Q4 		$699K Buy
18,500
+1,000
+6% +$36.8K 0.02% 818
2021
Q3 		$577K Buy
+17,500
New +$682K 0.01% 822
2020
Q2 		– Sell
-1,500
Closed -$88K – 1946
2020
Q1 		$88K Buy
+1,500
New +$122K 0.01% 628

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prelude Capital Management's AXSM Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,520 shares worth $372K. The stake represents 0.03% of the portfolio and ranks #652 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in AXSM as recently as Q4 2025.

Prelude Capital Management first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $389K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Prelude Capital Management held 1,520 shares of Axsome Therapeutics worth $372K as of Q2 2026.
  • Axsome Therapeutics was a new Prelude Capital Management position in Q2 2026.
  • Axsome Therapeutics made up 0.03% of Prelude Capital Management's portfolio in Q2 2026, its #652 holding.
  • Prelude Capital Management first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Prelude Capital Management's Axsome Therapeutics position peaked at $389K in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.